"This investment from the EIB enables us to accelerate our R&D timeline, ensuring we continue innovating to deliver a long-lasting impact in the immunotherapy space" states Hugo de Wit, CEO of LUMICKS.
"By providing deeper insights into cellular interactions, our instruments empower researchers to make faster, better-informed decisions, to improve success rates in clinical trials, and accelerate the development of effective therapies," adds de Wit.
LUMICKS aims to accelerate drug discovery in cancer research and advance understanding at the molecular and cellular levels, addressing a critical challenge in immunotherapy.
By providing a high-throughput measurement of interactions, the platform empowers researchers to optimize therapies faster and with greater accuracy, impacting over 1 million lives by 2027.
Collection
[
|
...
]